Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 485645, 8 pages
http://dx.doi.org/10.1155/2014/485645
Research Article

Mutation Analysis of JAK2V617F, FLT3-ITD, NPM1, and DNMT3A in Chinese Patients with Myeloproliferative Neoplasms

Department of Hematology, Qilu Hospital, Shandong University, 107 West Wenhua Road, Jinan 250012, China

Received 12 December 2013; Revised 14 February 2014; Accepted 16 February 2014; Published 11 May 2014

Academic Editor: Gautam Sethi

Copyright © 2014 Min Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. M. Klco, R. Vij, F. H. Kreisel, A. Hassan, and J. L. Frater, “Molecular pathology of myeloproliferative neoplasms,” American Journal of Clinical Pathology, vol. 133, no. 4, pp. 602–615, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. L. Martínez-Avilés, C. Besses, A. Álvarez-Larrán, E. Torres, S. Serrano, and B. Bellosillo, “TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms,” Annals of Hematology, vol. 91, no. 4, pp. 533–541, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. O. Abdel-Wahab, “Genetics of the myeloproliferative neoplasms,” Current Opinion in Hematology, vol. 18, no. 2, pp. 117–123, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Tefferi, “Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1,” Leukemia, vol. 24, no. 6, pp. 1128–1138, 2010. View at Google Scholar · View at Scopus
  5. R. Luthra, F. Vega-Vazquez, W. Chen et al., “Activating FLT3 mutations are detectable in chronic and blast phases of chronic myeloproliferative disorders other than chronic myeloid leukemia,” American Journal of Clinical Pathology, vol. 126, no. 4, pp. 530–533, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Nakao, S. Yokota, T. Iwai et al., “Internal tandem duplication of the flt3 gene found in acute myeloid leukemia,” Leukemia, vol. 10, no. 12, pp. 1911–1918, 1996. View at Google Scholar · View at Scopus
  7. G. Yoshimoto, T. Miyamoto, S. Jabbarzadeh-Tabrizi et al., “FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation,” Blood, vol. 114, no. 24, pp. 5034–5043, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Nakajima, F. Shibata, H. Kumagai, K. Shimoda, and T. Kitamura, “Tyk2 is dispensable for induction of myeloproliferative disease by mutant FLT3,” International Journal of Hematology, vol. 84, no. 1, pp. 54–59, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. N. Daver, P. Strati, E. Jabbour et al., “FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia,” American Journal of Hematology, vol. 88, no. 1, pp. 56–59, 2013. View at Google Scholar
  10. L. Li, O. Piloto, H. B. Nguyen et al., “Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model,” Blood, vol. 111, no. 7, pp. 3849–3858, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Bains, R. Luthra, L. J. Medeiros, and Z. Zuo, “FLT3 and NPM1 mutations in myelodysplastic syndromes: frequency and potential value for predicting progression to acute myeloid leukemia,” American Journal of Clinical Pathology, vol. 135, no. 1, pp. 62–69, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Sportoletti, S. Grisendi, S. M. Majid et al., “Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse,” Blood, vol. 111, no. 7, pp. 3859–3862, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. S. H. Chou, B. S. Ko, J. S. Chiou et al., “A knock-in Npm1 mutation in mice results in myeloproliferation and implies a perturbation in hematopoietic microenvironment,” PloS ONE, vol. 7, no. 11, Article ID e49769, 2012. View at Google Scholar
  14. B. Falini, C. Mecucci, E. Tiacci et al., “Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype,” The New England Journal of Medicine, vol. 352, no. 3, pp. 254–266, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Brecqueville, N. Cervera, V. Gelsi-Boyer et al., “Rare mutations in DNMT3A in myeloproliferative neoplasms and myelodysplastic syndromes,” Blood Cancer Journal, vol. 1, no. 5, article e18, 2011. View at Google Scholar
  16. O. Abdel-Wahab and A. T. Fathi, “Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy,” Advances in Hematology, vol. 2012, Article ID 469592, 12 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. T. J. Ley, L. Ding, M. J. Walter et al., “DNMT3A mutations in acute myeloid leukemia,” The New England Journal of Medicine, vol. 363, no. 25, pp. 2424–2433, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. J. W. Vardiman, J. Thiele, D. A. Arber et al., “The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes,” Blood, vol. 114, no. 5, pp. 937–951, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. M. L. Randi, E. Ruzzon, F. Tezza et al., “JAK2V617F mutation is common in old patients with polycythemia vera and essential thrombocythemia,” Aging—Clinical and Experimental Research, vol. 23, no. 1, pp. 17–21, 2011. View at Google Scholar · View at Scopus
  20. J. Zhou, Y. Ye, S. Zeng et al., “Impact of JAK2 V617F mutation on hemogram variation in patients with non-reactive elevated platelet counts,” PLoS ONE, vol. 8, no. 2, Article ID e57856, 2013. View at Google Scholar
  21. A. Carobbio, G. Finazzi, V. Guerini et al., “Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: Interaction with treatment, standard risk factors, and Jak2 mutation status,” Blood, vol. 109, no. 6, pp. 2310–2313, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. B. Xu, G. Chen, X. Luo, and J. Tang, “Detection of FLT3/ITD gene mutations in patients with hematologic malignancy and their clinical significance,” The Chinese-German Journal of Clinical Oncology, vol. 8, no. 2, pp. 100–103, 2009. View at Google Scholar
  23. R. Grundler, C. Miething, C. Thiede, C. Peschel, and J. Duyster, “FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model,” Blood, vol. 105, no. 12, pp. 4792–4799, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. L. M. Kelly, Q. Liu, J. L. Kutok, I. R. Williams, C. L. Boulton, and D. G. Gilliland, “FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model,” Blood, vol. 99, no. 1, pp. 310–318, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. B. H. Lee, I. R. Williams, E. Anastasiadou et al., “FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model,” Oncogene, vol. 24, no. 53, pp. 7882–7892, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Li, E. Bailey, S. Greenblatt, D. Huso, and D. Small, “Loss of the wild-type allele contributes to myeloid expansion and disease aggressiveness in FLT3/ITD knockin mice,” Blood, vol. 118, no. 18, pp. 4935–4945, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Pardanani, T. L. Reeder, T. K. Kimlinger et al., “Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease,” Leukemia Research, vol. 27, no. 8, pp. 739–742, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Williams, H. H. Kelley, X. Meng, A. Prada, and D. Crisan, “FLT3 mutations in myeloproliferative neoplasms: the Beaumont experience,” Diagnostic Molecular Pathology, vol. 22, no. 3, pp. 156–160, 2013. View at Google Scholar
  29. K. Cheng, P. Sportoletti, K. Ito et al., “The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model,” Blood, vol. 115, no. 16, pp. 3341–3345, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. N. Bolli, E. M. Payne, C. Grabher et al., “Expression of the cytoplasmic NPM1 mutant (NPMc+) causes the expansion of hematopoietic cells in zebrafish,” Blood, vol. 115, no. 16, pp. 3329–3340, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. Zhang, M. Zhang, L. Yang, and Z. Xiao, “NPM1 mutations in myelodysplastic syndromes and acute myeloid leukemia with normal karyotype,” Leukemia Research, vol. 31, no. 1, pp. 109–111, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. Oki, J. Jelinek, M. Beran, S. Verstovsek, H. M. Kantarjian, and J. J. Issa, “Mutations and promoter methylation status of NPM1 in myeloproliferative disorders,” Haematologica, vol. 91, no. 8, pp. 1147–1148, 2006. View at Google Scholar · View at Scopus
  33. J. Rocquain, N. Carbuccia, V. Trouplin et al., “Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias,” BMC Cancer, vol. 10, article 401, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. T. Ernst, A. Chase, K. Zoi et al., “Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms,” Haematologica, vol. 95, no. 9, pp. 1473–1480, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Schnittger, U. Bacher, C. Haferlach et al., “Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms,” Leukemia, vol. 25, no. 4, pp. 615–621, 2011. View at Google Scholar · View at Scopus
  36. J. S. Welch, T. J. Ley, D. C. Link et al., “The origin and evolution of mutations in acute myeloid leukemia,” Cell, vol. 150, no. 2, pp. 264–278, 2012. View at Google Scholar
  37. M. J. Walter, L. Ding, D. Shen et al., “Recurrent DNMT3A mutations in patients with myelodysplastic syndromes,” Leukemia, vol. 25, no. 7, pp. 1153–1158, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. F. Stegelmann, L. Bullinger, R. F. Schlenk et al., “DNMT3A mutations in myeloproliferative neoplasms,” Leukemia, vol. 25, no. 7, pp. 1217–1219, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. O. Abdel-Wahab, A. Pardanani, R. Rampal, T. L. Lasho, R. L. Levine, and A. Tefferi, “DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms,” Leukemia, vol. 25, no. 7, pp. 1219–1220, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Lin, D. Yao, J. Qian et al., “Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome,” PLoS ONE, vol. 6, no. 10, Article ID e26906, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Brecqueville, J. Rey, F. Bertucci et al., “Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms,” Genes Chromosomes and Cancer, vol. 51, no. 8, pp. 743–755, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Tefferi, T. L. Lasho, O. Abdel-Wahab et al., “IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis,” Leukemia, vol. 24, no. 7, pp. 1302–1309, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. L. M. Gutiyama, D. F. Coutinho, M. V. Lipkin, and I. R. Zalcberg, “Myeloid neoplasias: what molecular analyses are telling us,” ISRN Oncology, vol. 2012, Article ID 321246, 7 pages, 2012. View at Publisher · View at Google Scholar
  44. E. Hatzimichael, G. Georgiou, L. Benetatos, and E. Briasoulis, “Gene mutations and molecularly targeted therapies in acute myeloid leukemia,” American Journal of Blood Research, vol. 3, no. 1, pp. 29–51, 2013. View at Google Scholar